The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

For over 30 years, the US has clung to an outdated and misguided war on testosterone, lumping it in with the anabolic ...

That is the conclusion of the much-anticipated Sudlow Review – carried out by Prof Cathie Sudlow, chief scientist of Health ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical ...

Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

CD40 agonists have had mixed results in cancer to date, with Roche discontinuing its selicrelumab candidate after ...

Read Deep Dive: Patients & Partnerships in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven ...

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical ...